Dengue vector management using insecticide treated materials and targeted interventions on productive breeding-sites in Guatemala.

Background: In view of the epidemiological expansion of dengue worldwide and the availability of new tools and strategies particularly for controlling the primary dengue vector Aedes aegypti, an intervention study was set up to test the efficacy, cost and feasibility of a combined approach of insecticide treated materials (ITMs) alone and in combination with appropriate targeted interventions of the most productive vector breeding-sites.

Methods: The study was conducted as a cluster randomized community trial using "reduction of the vector population" as the main outcome variable. The trial had two arms: 10 intervention clusters (neighborhoods) and 10 control clusters in the town of Poptun Guatemala.

Pre-existing bacterial infections, not stress fever, influenced previous studies which labeled Gerrhosaurus major an afebrile lizard species.

Early studies indicated that the Sudan plated lizard, Gerrhosaurus major, did not exhibit a febrile response when challenged with bacterial pyrogen. More recent results indicated that a 14-day antibiotic treatment regime produced a significant decrease (0.5 +/- 0.

California ground squirrel body temperature regulation patterns measured in the laboratory and in the natural environment.

Body temperature (Tb) was measured by telemetry in both laboratory maintained and natural environment California ground squirrels, Spermophilus beecheyi. Laboratory animals had a mean diurnal Tb of 37.5 degrees C under conditions of LD 14:10, 20 degrees C and 36.

A single-blind, placebo-controlled study of glycosaminoglycan-peptide complex ('Rumalon') in patients with osteoarthritis of the hip or knee.

A randomized, single-blind, placebo-controlled trial was carried out in 62 patients (30 with osteoarthritis of the hip, 32 with osteoarthritis of the knee) to examine the efficacy of glycosaminoglycan-peptide complex in the treatment of osteoarthritis. Patients received 8-week courses of trial medication, each consisting of intramuscular injections of 3 x 2 ml ampoules per week, alternating with 8-week periods free of trial medication, in addition to conventional drug therapy and physiotherapy, as required. After 2-years' treatment, glycosaminoglycan-peptide-treated patients showed significant improvements, as compared with placebo, in relation to night pain, pain during the day, joint mobility and walking ability.